Lixte Biotechnology Holdings Inc Stock price
Is Lixte Biotechnology Holdings Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.
Key metrics
Don't miss a Thing! We will send you all news about Lixte Biotechnology Holdings Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Lixte Biotechnology Holdings Inc Stock News
Company Profile
Lixte Biotechnology Holdings, Inc. engages in the development of drugs for cancer treatment. The firm uses biomarker technology to identify enzyme targets associated with serious common diseases and designs novel compounds to attack those targets. Its product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The company was founded by John S. Kovach and Robert B. Royds on August 9, 2005 and is headquartered in East Setauket, NY.
| Head office | United States |
| CEO | Mr. Pursglove |
| Employees | 2 |
| Founded | 2005 |
| Website | lixte.com |


